Completed PHASE1 INTERVENTIONAL 6-arm NCT03031535

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin® Injection in Healthy Adult Volunteers

Sponsor: Dauntless Pharmaceuticals

Conditions Healthy Volunteer Study

Interventions Arginine hydrochloride Growth hormone-releasing hormone Intranasal octreotide acetate Subcutaneous octreotide acetate

Updated 6 times since 2017 Last updated: May 11, 2017 Started: Jan 31, 2017 Primary completion: Mar 31, 2017 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03031535, this PHASE1 trial focuses on Healthy Volunteer Study and remains completed. Sponsored by Dauntless Pharmaceuticals, it has been updated 6 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dauntless Pharmaceuticals

Data source: Dauntless Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States